Press Releases - Bristol Myers Squibb
Receive updated news from preferred websites, which are sent directly to the user's news reader. This includes the headlines, summaries and links to the full article on the website. Learn how
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
Mar 18, 2024 · Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024. Advisors. Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & …
Corporate news details - Bristol Myers Squibb
Sep 9, 2022 · Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
Dec 26, 2023 · PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash ...
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
Jun 3, 2022 · NEW YORK & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously …
Corporate news details - Bristol Myers Squibb
Jun 24, 2022 · Bristol Myers Squibb: Creating a Better Future for People with Cancer. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Bristol Myers Squibb Announces Leadership Transition Plan
Apr 26, 2023 · NEW YORK--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire as Chief Executive Officer, effective November 1, 2023. Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer ...
Bristol Myers Squibb Strengthens Neuroscience Portfolio with ...
Dec 22, 2023 · PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion ...
Corporate news details - Bristol Myers Squibb
Oct 8, 2023 · Bristol Myers Squibb and Mirati make available free of charge at Bristol Myers Squibb’s website at www.bms.com/investors and Mirati’s website at www.ir.mirati.com, respectively, copies of materials they file with, or furnish to, the SEC.
Corporate news details - Bristol Myers Squibb
Dec 12, 2022 · Bristol Myers Squibb is investigating two novel CELMoD agents, mezigdomide and iberdomide, for multiple myeloma that were intentionally designed to improve upon the demonstrated efficacy of the IMiD ® agents, along with manageable tolerability, ease of administration, and the potential to improve patient outcomes. These agents co-opt cereblon ...